Cardiac Dimensions Inc.'s Carillon mitral contour system is moving closer to competing in the US mitral repair market with the start of the 400-patient CARILLON pivotal trial at about 50 sites, mostly in the US.
US FDA has approved an investigative device exemption for a trial that will randomize patients with symptomatic functional mitral valve regurgitation (FMR) associated with heart failure to either treatment with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?